---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024177"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:15:14.389763+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q3 2022 net loss of $7.4M; updates on INB-100 and INB-400 programs

## Summary
- Net loss of $7.4M ($0.34/share) for Q3 2022 vs $3.4M ($0.25) in Q3 2021; R&D expenses rose to $4.3M.
- Cash of $27.6M as of Sep 30, 2022, down from $37.0M at Dec 31, 2021; raised $9.8M net from equity offering.
- INB-100 Phase 1: all three high-risk AML patients show durable morphologic CR >1 year; two >2 years; no DLTs; ASH data planned.
- Filed IND for INB-400; partnered with Univ of Louisville for GMP manufacturing for Phase 2 trial.
- Appointed Kenneth LaMontagne as SVP Business Development; added Dr. Michael Bishop to Scientific Advisory Board.

## SEC filing metadata
- accession: 0000950170-22-024177
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/0000950170-22-024177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/inab-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024177
- JSON: https://secwatch.observer/filing/0000950170-22-024177.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024177.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported the third quarter ended September 30, 2022 results: revenue $27.6 million, net income $7.4 million, or $0.34 per basic and diluted common share, EPS $0.34 per basic and diluted common share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $27.6 million
  - Net income: $7.4 million, or $0.34 per basic and diluted common share
  - EPS: $0.34 per basic and diluted common share
  - Result: reported results
  source text: of Louisville as the GMP manufacturing center for INB-400. • Strengthened the balance sheet through an equity offering raising net proceeds of $9.8 million; cash position of $27.6 million as of September 30, 2022. NEW YORK, Nov. 10, 2022 -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/0000950170-22-024177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.